Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Gene

SMARCA4

2 articles · Resources: NCBI Gene, OncoKB

Clinical · Molecular biology

The Pan-tumor Landscape, Allelic Status, and Genomic Complexity of SMARCA4 Alterations

Repetto M, Gormally MV, Chang J, et al.

Clinical cancer research

This large-scale pan-cancer study of nearly 69,000 tumor-normal pairs profiled by MSK-IMPACT characterizes the biological and clinical implications of SMARCA4 alterations across functional mutation classes and allelic configurations. SMARCA4 alterations were most frequently observed in thymic epithelial tumors (10.7%), non-small cell lung cancer (7.1%), bladder cancer (5.6%), and cervical cancer (5%). Distinct profiles of genomic complexity, co-mutations, and mutational signatures were associated with specific allelic states (monoallelic vs. biallelic) and mutation classes (class 1 vs. class 2). Preliminary data from a phase I trial of the BRM degrader PRT3789 revealed clinical benefit, including one complete response, among patients harboring monoallelic class 2 SMARCA4 alterations with preserved BRG1 expression.

Clinical · Molecular biology · Bioinfo & AI

Enrichment of SMARCA4 mutations in lung carcinomas presenting as cancer of unknown primary

Martinot T, Schonewille LHN, Ruano D, et al.

Lung cancer (Amsterdam, Netherlands)

This study investigates a simplified approach to identify lung origin in cancers of unknown primary (CUP). Researchers found that the presence of SMARCA4 mutations, combined with a history of smoking, is strongly associated with lung-origin CUP (CUP-Lung). This combination offers a 76% probability of lung origin, even without detectable pulmonary involvement. This method could serve as a surrogate for whole-genome sequencing (WGS) to guide organ-directed treatments.